VERA supply chain intelligence for Vera Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Vera Therapeutics, Inc. (VERA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ARES-TRADING-S-A | ARES-TRADING-S-A | 90% | If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| BOARD-OF-TRUSTEES-OF-LELAND-STANFORD-JUNIOR-UNIV | BOARD-OF-TRUSTEES-OF-LELAND-STANFORD-JUNIOR-UNIV | 90% | If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG | NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG | 90% | If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| OFCF-II | OFCF-II | 90% | The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| OFCF-III | OFCF-III | 90% | The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| OFCF-IV | OFCF-IV | 90% | With respect to the new lender, OFCF IV, the Company accounted for this transaction as an issuance of debt |
| OXFORD-FINANCE | OXFORD-FINANCE | 90% | The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| AUPH | Aurinia Pharmaceuticals Inc. | 72% | Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH g… |
| AUPH | Aurinia Pharmaceuticals Inc. | 72% | experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| CLYM | Climb Bio, Inc. | 72% | Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candid… |
| JBIO | Jade Biosciences, Inc. | 72% | Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our e… |
| SNYNF | Sanofi | 72% | experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance th… |
| TVTX | Travere Therapeutics, Inc. | 72% | Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance tha… |
| TVTX | Travere Therapeutics, Inc. | 72% | experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc. | 72% | Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: competing technological and market developments; • maintaining our rights under our existing license agreements and a… |
| AUPH | Aurinia Pharmaceuticals Inc. | 72% | competing technological and market developments; • maintaining our rights under our existing license agreements and any similar agreements we may enter into in the future; • negotiating favorable ter… |
| NVSEF | Novartis AG | 72% | SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS An investment in shares of our common stock involves a high degree of risk. Below is a list of some of the material risks associated with our business. T… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from VERA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VERA graph: SUMMARY OF RISKS ASSOCIATED WITH … |
| SNYNF | Sanofi | 72% | competing technological and market developments; • maintaining our rights under our existing license agreements and any similar agreements we may enter into in the future; • negotiating favorable ter… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VERA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VERA graph: Reciprocal relationship from SNYN… |
| TVTX | Travere Therapeutics, Inc. | 72% | competing technological and market developments; • maintaining our rights under our existing license agreements and any similar agreements we may enter into in the future; • negotiating favorable ter… |
| TVTX | Travere Therapeutics, Inc. | 72% | Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from TVTX g… |
| AMPLYX-PHARMACEUTICALS-INC | AMPLYX-PHARMACEUTICALS-INC | 62% | oduct candidates will be limited and the potential for successfully growing our business will be harmed. International trade policies, including tariffs, sanctions and trade barriers may adversely af… |
| AMRX | Amneal Pharmaceuticals, Inc. | 62% | Reciprocal relationship from AMRX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AMRX g… |
| ASAHI-KASEI-CORP | ASAHI-KASEI-CORP | 62% | competing technological and market developments; • maintaining our rights under our existing license agreements and any similar agreements we may enter into in the future; • negotiating favorable ter… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | isks. From time to time, we may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technolog… |
| MEMO-THERAPEUTICS-AG | MEMO-THERAPEUTICS-AG | 62% | competing technological and market developments; • maintaining our rights under our existing license agreements and any similar agreements we may enter into in the future; • negotiating favorable ter… |
| NASDAQ-STOCK-MARKET-LLC | NASDAQ-STOCK-MARKET-LLC | 62% | (including our clinical trial activities) in an effort to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain spec… |
| NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG | NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG | 62% | SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS An investment in shares of our common stock involves a high degree of risk. Below is a list of some of the material risks associated with our business. T… |
| OXFORD-FINANCE-LLC | OXFORD-FINANCE-LLC | 62% | 2024 2023 AMOUNT % Other income and expenses, net $ 15,023 $ 6,023 $ 9,000 149 % 95 Other income and expenses, net, increased by $9.0 million, or 149%, to $15.0 million in the year ended December 31,… |
| USA-LLC | USA-LLC | 62% | ths ended March 31, 2025, primarily due to a decrease of $0.5 million in interest income from a decrease in the average balance of marketable securities held during the three months ended March 31, 2… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| VERA-DEBT-13326 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| VERA-DEBT | Debt stack $75.2M | 90% | Market cache reports total debt of $75.2M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| VERA-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 90% | 13F overlay lists Avoro Capital Advisors LLC as top holder; 232 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CSLLY | CSL Limited | 100.00 | 2 | |
| AMRX | Amneal Pharmaceuticals, Inc. | 100.00 | 1 | ['customer'] |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 1 | ['supplier'] |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 |